Â鶹ŮÓÅ

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • Â鶹ŮÓÅ Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • High Postcancer Medical Bills
  • Federal Workers’ Health Data
  • Cyberattacks on Hospitals
  • ‘Cheap’ Insurance

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Dec 16 2025

Full Issue

FDA Green-Lights Libido-Enhancing Drug For Postmenopausal Women

The drug, Addyi, was first approved a decade ago for premenopausal women but comes with some unpleasant side effects. Also: a warning to retailers about tainted formula, a lawsuit over paraquat and Parkinson's, and more.

U.S. health officials have expanded approval of a much-debated drug aimed at boosting female libido, saying the once-a-day pill can now be taken by postmenopausal women up to 65 years old. The announcement Monday from the Food and Drug Administration broadens the drug’s use to older women who have gone through menopause. The pill, Addyi, was first approved 10 years ago for premenopausal women who report emotional stress due to low sex drive. (Perrone, 12/15)

An influential anti-abortion group is rallying its supporters around the country to flood EPA with requests to add mifepristone — a drug used in more than two-thirds of all abortions — to a list of drinking water contaminants tracked by public utilities. The strategy by Students for Life of America to target EPA’s rule-making process, which grew out of a recent meeting with EPA staff, is the latest move in a yearslong crusade by abortion opponents to use environmental laws to restrict abortion. (Ollstein and Wittenberg, 12/15)

The US Food and Drug Administration sent warning letters to Target, Walmart, Kroger and Albertsons after some of the stores failed to remove recalled baby formula linked to a large infant botulism outbreak. The FDA said it communicated with the retailers about the recall repeatedly, even sending several emails requesting plans of action to comply with the recall, but none of the companies responded to the request. (Christensen, 12/15)

Sanofi agreed to pay US biotech Dren Bio as much as $1.8 billion, including $100 million upfront, as the French company expands a push to develop medicines for immune-system diseases. The two companies will use closely held Dren Bio’s platform to discover new drug candidates which Sanofi will then develop and commercialize, according to a statement Monday. The terms are largely made up of conditional payments to Dren Bio dependent on the experimental medicines reaching certain milestones. (Furlong, 12/15)

Paul Friday remembers when his hand started flopping in the cold weather – the first sign nerve cells in his brain were dying. He was eventually diagnosed with Parkinson’s, a brain disease that gets worse over time. His limbs got stiffer. He struggled to walk. He couldn’t keep living on his family farm. Shortly afterward, Friday came to believe that decades of spraying a pesticide called paraquat at his peach orchard in southwestern Michigan may be the culprit. (White, 12/15)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
  • Thursday, April 16
  • Wednesday, April 15
  • Tuesday, April 14
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 Â鶹ŮÓÅ